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Intraflagellar transport (IFT) complex is essential for the formation and functional 
maintenance of eukaryotic cilia which play a vital role in development and tissue 
homeostasis. However, the biochemical characteristics and precise functions of IFT 
proteins remain unknown. Here, we report MIP-T3, a human microtubule-interacting 
protein that has been recently identified as a novel conserved component of IFT 
complex, is an easily degradable protein in human cell lines. The protein degradation 
is mediated by the ubiquitin-proteasome system, and its C-terminal is required for 
ubiquitination and proteasome-mediated degradation of MIP-T3 protein. This study 





















MIP-T3 (microtubule-interacting protein associated with TRAF3), also termed as 
TNF Receptor-Associated Factor 3 Interacting Protein 1 (TRAF3IP1), has been first 
identified as a human protein that binds to tubulin/microtubules and TRAF3 [1], 
IL-13 receptor alpha1 [2], and Disrupted-in-Schizophrenia 1 (DISC 1) [3]. Recently, 
several genome- and proteome-wide studies in different organisms have demonstrated 
that MIP-T3/TRAF3IP1 is a novel conserved component of intraflagellar transport 
(IFT) complex, which is essential for the formation and functional maintenance of 
eukaryotic cilia [4-8], and more intriguingly, IFT system has recently been 
demonstrated that is expressed in non-ciliated hematopoietic cells, and plays an 
important role in immune synapse assembly and intracellular membrane trafficking in 
T lymphocytes [9]. Additionally, our proteomic study has recently demonstrated that 
MIP-T3 can interact with different cytoskeletal proteins, chaperones, and signaling 
proteins, suggesting MIP-T3 may be an important protein involved in several cellular 
processes [10].  
Cilia are highly conserved microtubule-based organelles that protrude from the 
surface of most eukaryotic cells. Cilia play diverse roles in cellular motility, sensory 
transduction and signaling processes critical in regulating vertebrate development and 
tissue homeostasis [11]. Defects in cilia structure or function lead to a wide range of 
human diseases and developmental disorders (ciliopathies) [12]. Accordingly, it can 
be considered that regulation of IFT protein stability is a key step in controlling the 
structure and function of cilia. Selective protein degradation is crucial for regulating a 
variety of basic cellular processes, including the control of cell signaling, regulation 
of cell cycle and division, modulation of the immune and inflammatory responses, 
and development and differentiation [13,14]. Rapid removal of cellular proteins is an 
important regulatory mechanism that can tightly control the expression and activity of 
a protein in eukaryotic cells. Thus, studying the degradation of IFT protein can 
provide valuable insights into understanding the regulation and cellular function of 
the protein.  
In this study, we investigated the stability of MIP-T3 protein in several human 
cell lines and found that MIP-T3 protein level is highly regulated; mainly mediated by 
the ubiquitin-proteasome system (UPS), and the C-terminal region is required for the 
UPS-mediated degradation of MIP-T3 protein. 
 
2. MATERIALS AND METHODS 
2.1. Cell Cultures 
HEK293 and A549 cells were grown in DMEM (Invitrogen), HeLa cells were 
cultured in MEM (Invitrogen), and HSC-2 cells were maintained in MEM alpha 
(Invitrogen). All of the media were supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin.  
2.2. Plasmid Constructs, Antibodies and Reagents 
Plasmids encoding human MIP-T3 gene and its deletion mutants, CL(aa211-625), 
C(aa411-625) and NL(aa1-410), were generated by the polymerase chain reaction 
(PCR) using DNA polymerase KOD plus (TOYOBO), and then sub-cloned into 
pCAGGS or pEGFP-C1 vectors. Each plasmid DNA was purified by PureLink™ 
HiPure Filter Plasmid Kit (Invitrogen) according to the manufacturer’s instructions, 
and confirmed by restriction mapping and DNA sequencing. Guinea pig polyclonal 
antibody against MIP-T3 was generated as described previously [10]. Goat polyclonal 
anti-MIP-T3 antibody (Santa cruz), Rabbit monoclonal anti-β-actin antibody 
(Epitomics) and rabbit polyclonal anti-GFP antibody (MBL) were commercially 
purchased. MG132 was purchased from Calbiochem, and E64D, 3-Methyladenine 
(3-MA), and cycloheximide (CHX) were purchased from Sigma-Aldrich. 
2.3. RT-PCR 
For RT-PCR analysis, cells were dissolved by TRIzol LS reagent (Invitrogen), 
and total RNA was extracted. One microgram of total RNA was then reverse 
transcribed with Transcriptor Universal cDNA master (Roche) using random hexamer 
primers. MIP-T3 and GAPDH were respectively amplified by PCR using the 
following primers: forward, 5’-CCTGAAAGAACAAACGAGCTGCTCC-3’; and 
reverse, 5’-GTGAACTCTGGACTCTTCTTCTCGC-3’, for MIP-T3 (expected length 
of product: 186bp); forward, 5’-AAGGTCGGAGTCAACGGATT-3’; and reverse, 
5’-CTGGAAGATGGTGATGGGATT-3’, for GAPDH (expected length of product: 
222bp). The PCR was performed with the following conditions: 30 cycles of 95 ºC for 
15sec and 65 ºC for 1min. Five microliters of each RT-PCR product was 
electrophoresed on a 10% polyacrylamide gel followed by ethidium bromide staining.  
2.4. Western blotting and immunoprecipitation 
Cells were lysed and analyzed by Western blotting as described previously [10]. 
Beta-actin or alpha-tubulin was used as a loading control. Proteins were visualized by 
ECL detection reagent (GE Healthcare Biosciences). The protein level was 
determined by scanning of band intensity and analyzed using the IMAGEJ software 
(NIH).  
For immunoprecipitation of ectopically expressed MIP-T3, a total of 5×106 HeLa 
cells were transiently transfected with 10μg of pCAGGS-MIP-T3 plasmid using 
Lipofectamine 2000 (Invitrogen) for 24 hours, then treated with MG132 (25μM) or 
DMSO (vehicle control) for further 12 hours, subsequently performed 
immunoprecipitation as described previously [10]. Proteins were separated by 10% 
SDS-PAGE, blotted on PVDF membranes and analyzed by Western blotting. 
Ubiquitinated proteins were detected using mouse anti-mono- and 
poly-ubiquitinylated conjugate antibody (FK2H) (Enzo Life Sciences). 
2.5. Analysis of protein stability 
Cells were seeded in 24-well plate, transfected with 1μg of pCAGGS-MIP-T3 per 
well, and then incubated at 37 ºC for 24, 48, 72 and 96 hours. Cells were harvested at 
the indicated time points, lysed and subjected to 10% SDS-PAGE, and analyzed by 
Western blotting using anti-MIP-T3 antibody and anti-β-actin antibody.  
To analyze the stability of MIP-T3 protein and its truncation mutants, A549 cells 
were transiently transfected with MIP-T3 or its mutants for 18 hours, then further 
treated with CHX (100μg/ml) for 3, 6, 12, 18, 24 and 30 hours, respectively. Cells 
were lysed at the indicated time points and analyzed by Western blotting.  
To examine the effect of MG132, E64D or 3-MA on degradation of MIP-T3 
protein, MIP-T3-transfected A549 cells were treated with CHX (100μg/ml) combined 
with a range of concentrations of MG132 (5-50μM), E64D (25-200μM) or 3-MA 
(5-25mM) for 18 hours, respectively, and then analyzed by Western blotting.  
 
3. RESULTS  
3.1 Ectopically expressed MIP-T3 is rapidly degraded in human cells 
Since MIP-T3 mRNA has been demonstrated that is ubiquitously expressed in all 
of the tested tissues and cell lines in previous report [1], we first confirmed the mRNA 
and protein expression level of MIP-T3 in A549, HeLa and HSC-2 cells in this study. 
We found that the intrinsic MIP-T3 protein was hardly detected by Western blotting 
using specific anti-MIP-T3 antibody, although MIP-T3 mRNA is normally detectable 
(Fig. S1). These results suggest that steady-state level of MIP-T3 protein is kept 
extremely low or unstable in these human cell lines. Furthermore, we found that 
exogenously expressed MIP-T3 protein was rapidly decreased from 48 hours, and 
disappeared at 96 hours after transfection (Fig. 1A and B).  
To confirm whether the degradation of MIP-T3 protein is due to the reduction of 
mRNA level, we investigated the MIP-T3 mRNA level using a semi-quantitative 
RT-PCR analysis. As shown in Fig. 1C and 1D, there was no significant 
time-dependent change in MIP-T3 mRNA expression in the transfected cells, 
suggesting the reduction of MIP-T3 protein was due to protein degradation rather than 
the change of mRNA level.  
To further define the protein degradation is attributed to its protein nature, we 
compared the expression of GFP-fused MIP-T3 to GFP protein in human cells after 
transfection. As shown in Fig. 1E, GFP-fused MIP-T3 expressing cells were 
time-dependently reduced, but the GFP-expressing cells remain unchanged during 96 
hours of transfecion. In addition, co-transfection of GFP and GFP-MIP-T3 also 
demonstrated that only GFP-MIP-T3 was specifically degraded in a time-dependent 
manner (Fig. 1F). These results strongly suggest that MIP-T3 is a relatively easily 
degradable protein in these cells. 
 
 
3.2 Degradation of MIP-T3 is mediated by ubiquitin/proteasome pathway 
Generally, protein degradation in eukaryote cells is mediated by two major 
pathways, ubiquitin-proteasome pathway and autophagy-lysosome pathway [15]. To 
determine which proteolytic pathway is responsible for MIP-T3 degradation in human 
cell lines, we tested several protease inhibitors for their inhibitory effects on MIP-T3 
protein degradation in A549 cells. As shown in Fig. 2A, treatment with the 
proteasome inhibitor MG132 restored the expressing level of MIP-T3 protein. In 
contrast, the cysteine protease inhibitor E64D, which inhibits calpain and lysosomal 
proteases, had no significant effect on MIP-T3 protein degradation. Interestingly, 
3-Methyladenine (3-MA), an autophagy inhibitor, could partially rescue MIP-T3 
protein degradation.  
We further performed a CHX-chase assay by the addition of CHX combined with 
different concentrations of MG132, E64D and 3-MA to log-phase cultures followed 
by lysis at the indicated times. As shown in Fig. 2B and 2C, treatment with MG132, 
but not with E64D effectively inhibited MIP-T3 protein degradation in a 
dose-dependent manner. Whereas, 3-MA only partially inhibited the degradation 
treated at high concentration (Fig. 2D). These results suggest that MIP-T3 protein 
degradation is mainly mediated by proteasome degradation pathway. 
Since polyubiquitination of protein is essential for proteasome-mediated 
proteolysis, we further confirmed that the effect of MG132 treatment on accumulation 
of polyubiquitinated cellular proteins. As shown in Fig. 2E, total polyubiquitinated 
proteins increased in the MG132-treated HeLa cells. Furthermore, 
immunoprecipitation experiment demonstrated that MIP-T3 protein level was 
increased by MG132 treatment (Fig. 2F), in which polyubiquitinated proteins were 
also accumulated (Fig. 2G).  
 
3.3 Endogenous MIP-T3 degradation is also mediated by ubiquitin/proteasome 
pathway 
To investigate whether the endogenous MIP-T3 is also easily degraded in human 
cells, we first examined the turnover of endogenous MIP-T3 by a CHX chase analysis 
combined with immunoprecipitation experiment. As showed in Fig 3A and 3B, after 
inhibition of protein synthesis by CHX treatment, the immunoprecipitated 
endogenous MIP-T3 protein level decreased in a time-dependent manner, suggesting 
that the endogenous MIP-T3 protein is rapidly degraded in these human cells.  
We further confirmed the effects of MG132 on accumulation of endogenous 
MIP-T3 by a Western blotting/immunoprecipitation analysis. As shown in Fig. 3C, 
although the total polyubiquitinated proteins significantly accumulated in 
MG132-treated cells, but the endogenous MIP-T3 is still hardly detectable by Western 
blotting. Whereas, after enrichment by immunoprecipitation with anti-MIP-T3 
antibody, the intrinsic MIP-T3 protein could be detected and was time-dependently 
increased following MG132 treatment, accompanying the increased levels of total 
polyubiquitinated protein in the cells (Fig. 3D). Taken together, these results 
demonstrated that the proteasome inhibition increased endogenous MIP-T3 protein 
level as well as elevated level of polyubiquitinated proteins, suggesting the intrinsic 
MIP-T3 protein degradation may be also mediated by ubiquitin/proteasome pathway. 
 
3.4 The C-terminus of MIP-T3 protein is crucial for its degradation  
To determine if there are conserved regions in MIP-T3 protein responsible for 
protein degradation and ubiquitination, we constructed several truncation mutants of 
MIP-T3 (Fig. 4A), and expressed them in HeLa cells (Fig. 4B). As shown in Fig. 4C, 
after CHX treatment, the expression levels of MIP-T3 and the mutants with the 
C-terminus (MIP-T3-CL and MIP-T3-C) significantly reduced in a time-dependent 
manner. In contrast, the mutant lacking C-terminal 215 amino acids (MIP-T3-NL) 
displayed resistance to degradation. The estimated half-life of exogenously expressed 
MIP-T3, MIP-T3-CL and MIP-T3-C protein were 21.7±2.7，14.8±1.1 and 17.8±6.6 
hours, respectively, but that of MIP-T3-NL was 115 hours (Fig. 4D), indicating that 




3.5 The C-terminal region of MIP-T3 is required for its ubiquitination 
To further confirm if the C-terminal region was required for ubiquitination of 
MIP-T3 protein, we expressed GFP-fused MIP-T3 (pEGFP-MIP-T3) and the 
GFP-fused truncation mutants in HeLa cells and then immunoprecipitated them using 
anti-GFP antibody. As shown in Fig 5A, GFP-fused MIP-T3 and its mutants were 
immunoprecipitated, respectively (upper panel). Wild-type MIP-T3, MIP-T3-CL and 
MIP-T3-C variants appeared to have significantly higher level of polyubiquitination 
than MIP-T3-NL (lower panel). Moreover, the relative ratios of bound 
polyubiquitinated proteins to GFP-MIP-T3 and its mutants were calculated 
respectively and summarized in Fig. 5B, deletion of C-terminal region of MIP-T3 
(residues 411 and 625) abolished polyubiquitination of MIP-T3, suggesting the 
C-terminal is crucial for its polyubiqutination. 
 
4. DISCUSSION  
Recently, the ubiquitin-proteasome system (UPS) has been reported to be 
involved in the disassembly of cilia and flagella. During ciliary resorption, the 
ubiquitin conjugation system is present in cilia and adds an ubiquitin tag to axonemal 
turnover and breakdown products such as alpha-tubulin, which are transported by 
retrograde IFT complex to the cell body and can be reutilized in making new cilium 
[16]. However, whether the IFT proteins are also ubiquitinated during shortening 
process and the fates of these IFT proteins after ciliary resorption is still unclear. In 
mammalian cells, cilia and flagellar disassembly (also called resorption or shortening) 
occurs normally in synchrony with the cell cycle. Cilia must be removed before cell’s 
entry into mitosis perhaps because the ciliary basal body must be freed from the 
cilium to become the centriole that helps form the mitotic spindle [17]. The present 
study for the first time showed that endogenously, or ectopically expressed MIP-T3 
protein is indeed ubiquitinated and degraded via proteasome pathway in human cells, 
indicating the UPS may be involved in the regulation of IFT protein stability.  
Notably, the C-terminal truncation inhibited the degradation and 
polyubiquitination of MIP-T3 protein, suggesting the C-terminus is required for its 
proteasomal degradation and polyubiquitination of MIP-T3. In most proteins, the 
preferred acceptor site for polyubiquitin chain addition is a lysine side chain. MIP-T3 
sequence analysis confirmed that the C-terminus of MIP-T3 contains rich lysine 
residues, supporting the possibility that the major ubiquitin conjugation site is 
localized in the C-terminus of MIP-T3. Furthermore, the C-terminus also contains 
conserved coiled-coil domain, a protein-protein interacting interface [1], which is 
conserved in a number of IFT proteins (IFT81, IFT74/72, IFT57/55 and IFT20) [18]. 
Therefore, it is also possible the site is required for polyubiquitination mediated by E3 
ubiquitin ligases, although the role of the conserved coiled-coil domain on regulation 
of IFT protein stability was not clarified in this study.   
Moreover, multiple chaperone-assisted degradation pathways including CAP 
(chaperone-assisted proteasomal degradation), CASA (chaperone-assisted selective 
autophagy), and CMA (chaperone-mediated autophagy) have also been reported [19]. 
Within these pathways chaperones facilitate the sorting of non-native proteins to the 
proteasome and the lysosomal compartment and represent an essential aspect of 
cellular proteostasis. Since our previous study demonstrated MIP-T3 can interact with 
chaperones, including heat shock protein 90 (HSP90), heat shock 70 kDa protein 
(HSP70), heat shock cognate 71 kDa protein (Hsc70), whether the interaction 
between MIP-T3 and these chaperones might contribute to its stability regulation via 
chaperone-assisted degradation needs further study. The present results show that 
3-MA treatment had partial inhibitory effect on the MIP-T3 protein degradation, thus 
the CMA pathway may also partially involve in the degradation of exogenously 
expressed MIP-T3. However, more recently, 3-MA, the most commonly used 
pharmacologic inhibitor of autophagy, has been shown that has dual role in 
modulation of autophagy, there are marked increases of the autophagic markers in 
cells treated with 3-MA in full medium for a prolonged period of time (up to 9 h), 
especially when used at high concentrations [20]. Therefore, the underlying 
mechanism of 3-MA treatment on MIP-T3 protein degradation needs further 
experiments to elucidate. 
In conclusion, the present study revealed that MIP-T3 protein level in different 
human cell lines is regulated via the ubiquitin-proteasome degradation pathway. The 
C-terminal region of MIP-T3 is required for ubiquitination and the 
proteasome-dependent degradation of MIP-T3. This study provides the first evidence 
for regulation of IFT protein stability.  
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Fig. 1 Time-dependent degradation of MIP-T3 protein in different human cells 
(A) Western blot analysis for expressions of MIP-T3 and β-actin in A549, HeLa and HSC-2 cells, 
which was transiently transfected with pCAGGS-MIP-T3 for 24, 48, 72 and 96 hours, respectively. 
(B) Relative percentage of MIP-T3 level was time-dependently decreased during 96 hours of 
transfection. (C) Total cellular RNA was extracted from transfected cells, and the mRNA levels of 
MIP-T3 and GAPDH were respectively analyzed by RT-PCR. (D) No significant time-dependent 
changes in the MIP-T3 mRNA level was observed from 24 to 96 hours after transfection (E) 
Fluorescence microscopic observations of GFP and GFP-fused MIP-T3 expressed in A549 cells at 
the indicated time point after transfection. (F) Western blot analysis for GFP, GFP-fused MIP-T3, 




Fig. 2 MIP-T3 protein degradation was mediated by ubiquitin-proteasome pathway  
(A) Effects of various inhibitors treatment on MIP-T3 protein degradation. A549 cells were 
transiently transfected with pCAGGS-MIP-T3 and treated with various protease inhibitors, 
MG132 (25μM), E64D (25μM) and 3-MA (10mM) for the indicated period. DMSO was used as a 
vehicle control. (B) Dose-dependent effects of MG132 (5-50μM) on MIP-T3 degradation. (C) 
Effects of E64D (25-200μM) on MIP-T3 degradation. (D) Effects of 3-MA (5-25mM) on MIP-T3 
degradation. (E) Total cellular polyubiquitinated proteins are accumulated following 12 hours of 
treatment with MG132 (25μM) and DMSO (0.1% v/v, vehicle control). (F and G) MIP-T3 protein 
level increased in MG132-treated cells. Immunoprecipitation/Western blot analyses showed that 
MIP-T3 protein was polyubiquitinated in MG132-treated cells. The asterisk indicates IgG heavy 




Fig. 3 Intrinsic MIP-T3 degradation was mediated by ubiquitin-proteasome pathway 
(A) CHX-chase analysis of the intrinsic MIP-T3 turnover. Intrinsic MIP-T3 protein in DMSO or 
CHX treated HeLa cells were immunoprecipitated at the indicated time point and subject to 
Western blot analysis using anti-MIP-T3 antibody. Alpha-tubulin in each cell lysate was also 
detected as the loading control. (B) Relative percentage of the amount of intrinsic MIP-T3 protein 
normalized by α-tubulin protein level at the indicated time point relative to that at 0 hr. Error bars 
indicate mean values ± SD from three independent experiments. (C) Accumulation of the 
ubiquitinated proteins in HeLa cells which were treated with or without MG132 at 25μM for 6 and 
12 hr. Total cell lysates were prepared, and 1% of input was analyzed by Western Blotting. (D) 
The remaining lysates were analyzed by immunoprecipitation/Western blotting. MG132 treatment 
time-dependently increased the accumulation of endogenous MIP-T3 proteins as well as the 




Fig. 4 C-terminal region was crucial for degradation of MIP-T3 protein in cells 
(A) The schematic representation of MIP-T3 and its truncation mutants. (B) Western blot analysis 
of expressions of MIP-T3 and its mutants in A549 cells at 24 hours post-transfection. (C) 
Expressions of MIP-T3 and its mutants in A549 cells treated with CHX (100μg/mL) for the 
indicated period after 18 hours of transfection. (D) The estimated half-life of each protein was 
showed in lower panel. Data were presented as the means ± SD of three independent experiments. 
The asterisks indicate significant differences in protein expressing levels between the MIP-T3 NL 




Fig. 5 C-terminal region of MIP-T3 was required for ubiquitination. 
(A) HeLa cells were transfected with pEGFP, GFP-MIP-T3 and its GFP-tagged truncation 
mutants for 24 hours, respectively, and treated with MG132 for a further 12 hours, and then 
immunoprecipitated with polyclonal anti-GFP antibody. The immunoprecipitates were analyzed 
by Western blotting using anti-GFP (upper panel) and anti-ubiquitin (lower panel) antibodies. Ubn 
indicates polyubiquitinated proteins. The closed arrowheads indicate the position of each protein. 
(B) The relative ratio of bound multi-ubiquitinated proteins to GFP-MIP-T3 and its mutants. The 
asterisks indicate significant differences in relative protein levels between the MIP-T3 NL and the 
others, *P < 0.05, **P < 0.01. 
Fig. S1 MIP-T3 mRNA is ubiquitously expressed but its steady-state protein level is hardly 
detectable by Western blotting. 
(A) Total RNA was extracted from A549, HeLa and HSC-2 cells, and the mRNA levels of 
MIP-T3 and GAPDH were analyzed by RT-PCR, respectively. (B) Western blotting was 
performed using anti-MIP-T3 antibody, demonstrating that an 83kDa band in the positive control 
HeLa cells, which were transiently transfected with pCAGGS-MIP-T3, was not detected in all the 




> In this study we examine a novel IFT protein MIP-T3’s protein stability in human cells. > We found that 
endogenously, or ectopically expressed MIP-T3 protein is unstable. >The protein degradation is mediated by the 
ubiquitin-proteasome system. > The C-terminal is required for its ubiquitination and proteasome-mediated protein 
degradation. > We provide the first evidence for regulation of IFT protein stability. 
 
